One MedImmune Way
About MedImmune, LLC
MedImmune is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland with facilities in Pennsylvania, California, Kentucky, the United Kingdom, and the Netherlands. UK facilities include vaccine manufacturing operations in Speke and antibody discovery and research laboratories in Cambridge.
With two marketed products and an advancing pipeline of promising candidates in the areas of infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience, MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees.
352 articles with MedImmune, LLC
One year after spinning out from AstraZeneca’s MedImmune, Viela Bio is already anticipating filing a Biologics License Application with the U.S. Food and Drug Administration for its lead asset, inebilizumab.
Investors are showing some love to AstraZeneca on this Valentine’s Day after the company posted strong year-end results. Shares of AstraZeneca are up more than 6 percent in premarket trading on the strength of the company’s financial results.
Viela Bio, based in Gaithersburg, Md., announced that N-MOmentum, its Phase IIb pivotal trial of inebilizumab, met both primary and key secondary endpoints in neuromyelitis optica spectrum disorder (NMOSD).
AstraZeneca and its MedImmune division announced results from its Phase III EAGLE clinical trial. Imfinzi, in combination with tremelimumab, an anti-CTLA4 antibody, compared to standard-of-care (SoC) chemotherapy, failed to meet its primary endpoints in patients with recurrent or metastatic head ...
AstraZeneca Presents Clinical Research Advances for Blood Cancer Patients at 2018 American Society of Hematology Annual Meeting
27 scientific presentations, including long-term data from CALQUENCE in mantle cell lymphoma and updated early-phase trial results in chronic lymphocytic leukemia
AstraZeneca has spent the last seven years getting hammered by loss of patent protections on older drugs. However, this quarter marked a return to sales growth driven by high demand for its new drugs, especially in the oncology segment.
Virion Therapeutics, LLC Announces its Inaugural Board of Directors and Scientific Advisory Board Members
Virion Therapeutics, LLC today announced the appointment of its inaugural Board of Directors and Scientific Advisory Board.
AstraZeneca and its MedImmune division released data on overall survival (OS) in its Phase III PACIFIC clinical trial of Imfinzi (durvalumab).
AstraZeneca and its research-and-development arm, MedImmune, announced that the U.S. FDA approved Lumoxiti (moxetumomab pasudotox-tdfk) for adults with relapsed or refractory hairy cell leukemia (HCL) who have had at least two previous systemic therapies, including with a purine nucleoside analog.
US FDA Approves LUMOXITI™ (moxetumomab pasudotox-tdfk) for Certain Patients with Relapsed or Refractory Hairy Cell Leukemia
Approval of LUMOXITI, a first-in-class medicine for hairy cell leukemia, marks first new treatment option for patients in over 20 years
Job hunting can be a challenging time for people. Finding open positions that fit your skill set and then competing with other highly-qualified people can be bruising, especially if you’re already a bit damaged from a recent layoff.
4D Molecular Therapeutics snagged $90 million in a Series B financing round. The company intends to use the funds to advance its Therapeutic Vector Evolution platform and pipeline of next-generation AAV gene therapeutics.
AstraZeneca and MedImmune announced top-line results from its TULIP 1 Phase III clinical trial of anifrolumab in adults with moderate-to-severe systemic lupus erythematosus (SLE). Unfortunately, the drug didn’t meet the trials primary endpoint of statistically-significant reduction in disease act...
CBT Pharmaceuticals Strengthens Management Team with the Appointment of Yuling Li, PhD as Senior Vice President, Process Development and Manufacturing
CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, today announced a new global leadership structure and the appointment of Yuling Li, PhD as Senior Vice President, Process Development and Manufacturing.
Here’s a roundup of biopharma companies that have announced hiring trends since the beginning of the year.
ADC Therapeutics Doses First Patient in Pivotal Clinical Trial of ADCT-402 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase II clinical trial intended to support the submission of Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).
AstraZeneca’s MedImmune and 4D Molecular Therapeutics forged a collaboration to develop a gene therapy for chronic lung disease.
4D Molecular Therapeutics and MedImmune Collaborate to Design, Develop and Commercialize AAV Gene Therapy for Chronic Lung Disease
MedImmune and 4D Molecular Therapeutics announced a collaboration to develop and commercialize a gene therapeutic for patients with chronic lung disease, utilizing 4DMT’s novel discovery platform to generate optimized AAV vectors.
AstraZeneca to Share Latest Data from an Industry-Leading Portfolio That Aims to Advance Clinical Understanding of Diabetes and CV Risk Management at ADA 2018
AstraZeneca and MedImmune, will present 45 abstracts including seven late-breaking data disclosures from the Company’s Cardiovascular (CV), Renal and Metabolism (CVRM) therapy area at the American Diabetes Association’s (ADA) 78th Scientific Sessions
Moxetumomab Pasudotox Pivotal Data in Patients with Previously-Treated Hairy Cell Leukemia Presented at the 2018 ASCO Meeting
AstraZeneca and MedImmune, its global biologics research and development arm presented results from the Phase III (‘1053’) clinical trial (Abstract #7004) that evaluated moxetumomab pasudotox in 80 patients with relapsed or refractory hairy cell leukemia (HCL) who had received at least two prior lines of therapy.